GCG and metabolic dysfunction-associated steatotic liver disease: In recent years, glucagon-like peptide-1 (GLP-1) analogs and sodium-glucose co-transporter type-2 (SGLT2) inhibitors have been approved for the treatment of NAFLD [6,7].